Robotics Maestro's New Mission: Yulun Wang Joins AiM to Shape the Future of Brain Surgery

WORCESTER, Mass. – March 11, 2026 – In a move sending ripples through the medical technology industry, AiM Medical Robotics today announced that Dr. Yulun Wang, a titan of surgical robotics, has joined its Board of Directors. The appointment is a monumental endorsement for the Worcester-based company, which is developing a next-generation MRI-compatible robot designed to transform neurosurgery.

Dr. Wang is not just an industry veteran; he is a foundational architect of the entire field. As the founder of Computer Motion, he invented AESOP, the first surgical robot ever approved by the FDA. He was also the visionary behind the ZEUS robotic system, which famously performed the world's first remote transatlantic surgery in 2001. His subsequent venture, the telemedicine pioneer InTouch Health, was acquired by Teladoc for $1.1 billion in 2020. For AiM, a company advancing from its first human studies toward commercial launch, securing a director with such a legendary track record of innovation and successful market exits is a strategic masterstroke.

“Yulun's decision to join our Board is a powerful external validation of AiM's technology, strategy, and execution,” said Dr. Gregory Fischer, AiM's Chief Executive Officer and Founder. “He brings unmatched experience in building robotic platforms from concept through regulatory approval, market adoption, and strategic exit.”

A Pioneer’s Endorsement for a Pivotal Moment

Dr. Wang's influence is rooted in his ability to translate complex engineering into clinically adopted, commercially successful platforms. His career is a roadmap of the evolution of robotic and digital health. After Computer Motion's landmark merger with its rival Intuitive Surgical in 2003, which created the dominant force in surgical robotics today, Dr. Wang continued to break new ground. He currently serves as Executive Chairman of Sovato Health, a company focused on making remote surgery a commercial-scale reality, and as Chairman of the World Telehealth Initiative, a non-profit delivering medical expertise to underserved regions.

His decision to join AiM's board comes at what the company calls a “pivotal growth inflection point.” AiM is targeting a $10 billion addressable market for stereotactic neurosurgery, including procedures for Parkinson’s disease, depression, tremors, and tumor removal. Dr. Wang's involvement lends immense credibility to this ambition.

“AiM is addressing a clear unmet need at the intersection of neurosurgery, robotics, and advanced imaging,” Dr. Wang stated. “The company's MRI-compatible robotic architecture is both technically differentiated and commercially compelling. I see strong alignment between AiM's technology, its disciplined development strategy, and the requirements for long-term value creation.”

This sentiment was echoed by AiM's Chief Medical Officer, Dr. Jonathan Sackier, who has previously worked with Dr. Wang. “Having worked with him at Computer Motion and InTouch, I am personally familiar with his wisdom, drive, and refuse-to-lose attitude,” Dr. Sackier noted. “His insight will strengthen our clinical and business strategy and help ensure that our technology delivers measurable value to patients, providers, and healthcare systems.”

Tackling Neurosurgery's Elusive "Brain Shift" Problem

The core of AiM’s innovation lies in its approach to a persistent and critical challenge in neurosurgery: intraoperative brain shift. During surgery, after the skull is opened, the brain can move or change shape, rendering pre-operative MRI scans less accurate. This shift can lead to misplaced electrodes or incomplete tumor resections, with one study noting that up to 34% of deep brain stimulation (DBS) lead placements require revision or removal. AiM’s solution is a compact, portable robot designed to work inside the magnetic field of an MRI scanner.

This allows surgeons to see the brain and their instruments in real-time throughout the entire procedure, continuously compensating for brain shift and confirming the precise placement of tools. This capability represents a significant leap beyond systems that rely solely on pre-operative plans or require the patient to be moved between an imaging suite and an operating room. The technology is built upon a foundation of 15 years and $15 million in NIH-funded research.

AiM is now preparing to initiate its first-in-human clinical study for DBS in Parkinson's patients. The trial, conducted in collaboration with Brigham and Women's Hospital in its state-of-the-art Advanced Multimodality Image-Guided Operating (AMIGO) Suite, follows a successful cadaver trial that demonstrated the robot’s precision. This methodical, evidence-based approach is crucial as the company navigates the path to regulatory clearance.

Charting a Course in a Competitive Field

AiM enters a dynamic but competitive market. Established systems like Zimmer Biomet’s ROSA ONE Brain are widely used for robotic assistance in neurosurgery, and other innovators such as NeuroArm and neuro42 are also pushing the boundaries of technology. However, AiM’s unique value proposition—a portable robot that enables continuous, real-time guidance directly within the MRI environment—sets it apart.

To fund this ambitious journey, AiM has successfully raised $13.1 million to date. A pivotal $8.1 million Series A round, led by IQ Capital and 1540 Ventures, was closed in 2025 to fund the first-in-human study and accelerate product development. The company’s strategy also emphasizes capital efficiency and alignment with existing clinical reimbursement frameworks, a pragmatic approach designed to smooth the path to market adoption.

The Future: An Intelligent Surgical Ecosystem

Looking beyond its initial product launch, AiM has its sights set on integrating artificial intelligence to create what it calls an “intelligent surgical ecosystem.” The vision is for a robotic platform that doesn't just execute commands but learns from real-world data to optimize workflows, provide surgeons with predictive insights, and ultimately enhance decision-making in real time.

This forward-thinking plan aligns with the broader trajectory of medicine, where AI is increasingly used to analyze complex imaging, plan surgical strategies, and predict patient outcomes. By combining advanced robotics with intraoperative imaging and intelligent software, AiM aims to unlock a new era of neurosurgery that is not only more precise but also safer, faster, and more accessible to patients around the world.